Q2 2025 Earnings Call Transcript July 31, 2025 Amicus Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to highlight a groundbreaking ...

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

According to the authors, these findings highlight the potential of urine biomarkers as noninvasive indicators of ...

COPD study links increased alveolar macrophage carbon to worse lung function, inflammation, and altered cell phenotype.

Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab plus azacitidine, 22 have evaluable responses in the first twelve months of follow-up - Building upon previously reported ...

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

Certain urine biomarkers may noninvasively assess kidney health in patients with diabetic kidney disease and help identify ...

Adenosine deaminase 2 (ADA2) plays a critical role in immune regulation, particularly in monocyte differentiation and activation. Unlike ADA1, which primarily functions intracellularly, ADA2 can be ...

Detailed price information for Seastar Medical Hldg Corp (ICU-Q) from The Globe and Mail including charting and trades.

Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today ...

SeaStar Medical Holding Corporation a annoncé l’ajout d’un hôpital pédiatrique texan de renommée nationale à sa clientèle croissante d’utilisateurs de la thérapie QUELIMMUNE.